Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQ: TNXP · Real-Time Price · USD
0.236
+0.001 (0.21%)
At close: Jan 17, 2025, 4:00 PM
0.231
-0.004 (-1.91%)
Pre-market: Jan 21, 2025, 5:37 AM EST
TNXP Revenue
Tonix Pharmaceuticals Holding had revenue of $2.82M in the quarter ending September 30, 2024, a decrease of -29.26%. This brings the company's revenue in the last twelve months to $11.29M, up 183.05% year-over-year. In the year 2023, Tonix Pharmaceuticals Holding had annual revenue of $7.77M.
Revenue (ttm)
$11.29M
Revenue Growth
+183.05%
P/S Ratio
0.36
Revenue / Employee
$109,621
Employees
103
Market Cap
44.01M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
TNXP News
- 4 weeks ago - Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia - GlobeNewsWire
- 4 weeks ago - FDA accepts Tonix's NDA for non-opioid fibromyalgia drug TNX-102 SL - Invezz
- 4 weeks ago - Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application (NDA) for TNX-102 SL for Fibromyalgia - GlobeNewsWire
- 5 weeks ago - Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights - GlobeNewsWire
- 6 weeks ago - Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers - Accesswire
- 7 weeks ago - Tonix Pharmaceuticals to Participate in the NobleCon20 Investor Conference - GlobeNewsWire
- 2 months ago - Muscarinic Acetylcholine Receptor M1 Antagonists Pipeline Research Report 2024: Comprehensive Insights on 8+ Drugs Featuring Tonix Pharmaceuticals, BMS, WinSanTor, and Apnimed - GlobeNewsWire
- 2 months ago - Tonix Pharmaceuticals to Present at the Winter 2024 Investor Summit Virtual - GlobeNewsWire